Israeli Medical Startup Seeks Liquidation After Decade Without Revenue

Filterlex Medical, a medical device startup focused on cardiology, has filed an urgent request with the Haifa District Court for liquidation proceedings. The company, founded in 2015, developed a system to protect against embolisms during aortic valve replacement procedures, aiming to reduce stroke risk. Despite its decade of operation, Filterlex Medical has never generated revenue, relying solely on investor funding and research grants.

Dr. Shimon Eckhouse, founder of Lumenis and a prominent entrepreneur, is a director and shareholder in Filterlex Medical. He also established the Alon Medtech Ventures incubator in 2012, which supports companies in medical aesthetics and cardiology.

The company's filing states that it has ceased all operations, has no income, employees, or funding sources, and its debts significantly exceed its assets, totaling approximately 1.3 million shekels, largely owed to the European Union. The request highlights that in March 2025, results from a large-scale study on a competing product indicated low clinical benefit for devices like Filterlex's, casting doubt on the market potential for stroke prevention during cardiac catheterization.

Despite hopes that further clinical data would alter this assessment, the company's prospects diminished. The board of directors decided to close the company after unsuccessful attempts to attract strategic partners interested in acquiring its intellectual property. Attorney Achiad Harel, representing Filterlex, commented that the company's failure stemmed from new clinical findings revealing market issues and a reduction in EU grants, which the company disputes.

Filterlex Medical's shareholders include numerous individuals and corporations, both domestic and foreign. Dr. Eckhouse and Alon Medtech Ventures are identified as the largest shareholders.